Skip Nav Destination
Issues
1 November 2020
-
Cover Image
Cover Image
The vast majority of hepatocellular carcinomas (HCCs) arise in patients who have a long clinical history of chronic liver disease and cirrhosis. This presents an actionable window of opportunity to intervene prior to the development of clinically detectable cancer. In this issue, Chung and colleagues found that regenerative nodules from cirrhosis patient samples harbor numerous neoantigens, a putative target of cancer immunotherapy. They then sought to examine the efficacy of immune checkpoint inhibitors (ICIs) in preventing liver cancer in a chemical carcinogen-based mouse model of chronic liver damage and HCC. The cover shows whole section images of H&E-stained livers from these mice. Mice treated with anti-PD-1 antibody (lower right) prior to the formation of macroscopic liver tumors showed a significant reduction in tumor burden compared to mice treated with IgG control antibody (upper left). Additionally, anti-PD-1 treatment led to increased T-cell infiltration into the liver parenchyma, suggesting that adaptive immunity can be activated to increase immune-mediated surveillance and elimination of malignant clones. This study supports further clinical investigation into the use of ICIs in high-risk liver cirrhosis patients to prevent development of liver cancer. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1940-6207
EISSN 1940-6215
Issue Sections
Commentaries
Spotlight
Review
Research Articles
Primary Care Provider Beliefs and Recommendations About Colorectal Cancer Screening in Four Healthcare Systems
Nirupa R. Ghai; Christopher D. Jensen; Sophie A. Merchant; Joanne E. Schottinger; Jeffrey K. Lee; Jessica Chubak; Aruna Kamineni; Ethan A. Halm; Celette Sugg Skinner; Jennifer S. Haas; Beverly B. Green; Nancy T. Cannizzaro; Jennifer L. Schneider; Douglas A. Corley
Fecal Immunologic Test Results and Diagnostic Colonoscopy in a Mexican Population at Average Risk for Colorectal Cancer
Maria Del Carmen Manzano-Robleda; Priscilla Espinosa-Tamez; Michael B. Potter; Martin Lajous; Katherine Van Loon; Li Zhang; Alejandro Jimenez-Peña; Julio Sánchez Del Monte; Alejandro Mohar; Angélica Hernández-Guerrero
Breast Cancer Risk and Use of Nonsteroidal Anti-inflammatory Agents After a Benign Breast Biopsy
Mark E. Sherman; Robert A. Vierkant; Suneetha Kaggal; Tanya L. Hoskin; Marlene H. Frost; Lori Denison; Daniel W. Visscher; Jodi M. Carter; Stacey J. Winham; Matthew R. Jensen; Derek C. Radisky; Celine M. Vachon; Amy C. Degnim
Editor’s Note
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.